Cantor Fitzgerald’s Generation Bio GBIO Stock Holding History

Cantor Fitzgerald’s Portfolio GBIO Stock Details GBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-99,000	Closed	-$606K	–	269
2025 Q3	$606K	Buy	+99,000	New	+$513K	0.01%	275

Other funds holding GBIO

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

SCP

SymBiosis Capital Partners Bentonville, Arkansas $52.8M AUM

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Cantor Fitzgerald's GBIO Position: Q4 2025 in Review

Cantor Fitzgerald sold out of Generation Bio (GBIO) in Q4 2025, closing a stake of 99,000 shares — an estimated $606K sold.

Cantor Fitzgerald first reported a position in GBIO in Q3 2025 and held it in 1 quarter. The position peaked at $606K in Q3 2025. 48 funds tracked by Wall St. Rank hold GBIO as of Q4 2025.

Cantor Fitzgerald reported no remaining Generation Bio position as of Q4 2025 after selling out during the quarter.
Cantor Fitzgerald sold 99,000 Generation Bio shares in Q4 2025, an estimated $606K.
Cantor Fitzgerald first reported a position in Generation Bio in Q3 2025 and held it in 1 quarter.
Cantor Fitzgerald's Generation Bio position peaked at $606K in Q3 2025.
48 funds tracked by Wall St. Rank held Generation Bio as of Q4 2025.

Based on Cantor Fitzgerald's 13F filing for Q4 2025, filed 17 Feb 2026.